Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;7(4):1338-1340.
doi: 10.1016/j.jaip.2018.09.012. Epub 2018 Sep 25.

A retrospective analysis of esophageal eosinophilia in patients with aspirin-exacerbated respiratory disease

Ryan C Eid  1 , Marina L Palumbo  2 , Tanya M Laidlaw  2 , Kathleen M Buchheit  2 , Katherine N Cahill  3
Affiliations

A retrospective analysis of esophageal eosinophilia in patients with aspirin-exacerbated respiratory disease

Ryan C Eid et al. J Allergy Clin Immunol Pract. 2019 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: T Laidlaw has served on scientific advisory boards for GlaxoSmithKline and Allakos and has received consultancy fees from Knopp Biosciences and Sanofi-Genzyme. K Cahill has served on scientific advisory boards for Teva, Regeneron, and Optinose. R Eid, M Palumbo, and K Buchheit have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.. Flow diagram of study population
387 charts were reviewed for the presence of agreed-upon terms and then audited in detail for history and biopsy-proven EE. Of the 387 charts reviewed, 13 patients had a history of EE and 10 underwent aspirin desensitization. 9 of the 10 patients with EE were diagnosed with EE after initiation of daily aspirin therapy.
See this image and copyright information in PMC

References

    1. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000; 16:432–6. - PubMed
    1. Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003; 111:180–6. - PubMed
    1. Buchheit KM, Laidlaw TM. Update on the Management of Aspirin-Exacerbated Respiratory Disease. Allergy Asthma Immunol Res 2016; 8:298–304. - PMC - PubMed
    1. Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2015; 135:245–52. - PMC - PubMed
    1. Lee RU, White AA, Ding D, Dursun AB, Woessner KM, Simon RA, et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirinexacerbated respiratory disease. Ann Allergy Asthma Immunol 2010; 105:130–5. - PubMed

Publication types

MeSH terms